Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Keppra (levetiracetam) is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy as adjunctive therapy, and the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy as adjunctive therapy.
• This summary is based on the review of 24 systematic review(s)/meta-analysis(es). ^[1-24]
• Neonatal Seizures: Levetiracetam demonstrated no significant difference in seizure control compared to Phenobarbitone (RR: 1.11; 95% CI: 0.79, 1.54), though some studies noted better seizure control within 24 hours with Levetiracetam. Levetiracetam is associated with a lower incidence of hypotension, respiratory depression, and depressed sensorium compared to Phenobarbitone, with fewer overall side effects.
• Idiopathic Generalized Epilepsies (IGE): Levetiracetam was ranked as the most effective adjunctive therapy for myoclonic seizures.
• Drug-Resistant Focal-Onset Seizures in Children: Levetiracetam was found to be more effective than other antiseizure medications in achieving at least a 50% reduction in seizures and had the highest probability of achieving seizure freedom.
• Adjunctive Treatment for Drug-Resistant Focal Epilepsy: Levetiracetam was more effective than placebo in achieving a 50% or greater reduction in seizure frequency (RR 2.37, 95% CI 2.02 to 2.78). Levetiracetam is generally well-tolerated with minimal adverse effects, though it may potentially worsen behavior in children.
• Pediatric Convulsive Status Epilepticus: Levetiracetam shows lower recurrence rates and reduced intubation requirements when compared to Phenytoin.
• There is no population-type or subgroup information available in the reviewed studies.